Manuscripts

  1. Maxwell GL, Chandramouli GVR, Dainty L, Litzi T, Berchuck A, Barrett JC, Risinger JI. Microarray analysis of endometrial carcinomas and mixed mullerian tumors reveals distinct gene expression profiles associated with different histologic types of cancer. Manuscript in press at Clinical Cancer Research.
  2. Maxwell GL, Bidus MA, Kulasingam S, Rose GS, Elkas JC, Rodriguez M. Cost Effectiveness of cervix cancer screening in an organization that provides both salary and healthcare benefits. Submitted to Obstetrics and Gynecology
  3. Maxwell GL, Chandramouli GVR, Dainty L, Litzi T, Bidus M, Berchuck A, Barrett JC, Risinger JI. Racial disparity in global gene expression among patients with advanced endometrial adenocarcinoma. Being submitted to the Journal of Clinical Oncology
  4. Maxwell GL, Tian C, Risinger J, Brown C, Thigpen T, Fleming G, Gallion H, Brewster W. Racial Disparity in survival among patients with advanced/recurrent endometrial adenocarcinoma: A Gynecologic Oncology Group (GOG) Study. Being submitted to the Journal of Clinical Oncology
  5. Maxwell GL, Schildkraut JM, Calingaert B, Risinger JI, Dainty L, Marchbanks PA, Berchuck A, Barrett JC: Progestin and Estrogen Potency of Combination Oral Contraceptives and Endometrial Cancer Risk. Revised manuscript solicited and currently under review by the Journal of the National Cancer Institute.
  6. Risinger JI, Maxwell GL, Chandramouli GVR, Aprelikova O, Litzi T, Umar A, Berchuck A, Barrett JC. Gene Expression Profiling of Microsatellite Unstable and Microsatellite Stable endometrial cancers indicate distinct pathways of aberrant signaling. Cancer Research (in press).
  7. Winter III WL, Maxwell GL, Tian C, Sobel E, Rose GS, Thomas G, Carlson JW. Association of hemoglobin level with survival in cervical carcinoma patients treated with concurrent cisplatin and radiotherapy: a Gynecologic Oncology Group study. Gynecol Oncol 2004;94:495-501.
  8. Dainty L, Maxwell GL, Clarke-Pearson DL, Myers ER. Cost-effectiveness of combination thromboembolism prophylaxis in gynecologic oncology surgery.Gynecol Oncol 2004;93:366-73.
  9. Winter III WE, Maxwell GL, Tian C, Carlson JW, Ozois RF, Rose PG, Spriggs D, Armstrong DK, Muggia F, McGuire WP. Prognostic Factors for Advanced Epithelial Ovarian Cancer: A Gynecologic Oncology Group Study. Submitted to the Journal of Clinical Oncology
  10. Dainty L, Chandramouli GVR, Risinger JI, Litzi T, Barrett JC, Fowler J, Berchuck A, Morrison C, Maxwell GL: Over-expression of folate binding protein and mesothelin are associated with uterine papillary serous carcinoma (UPSC). Being submitted to Gynecologic Oncology.
  11. Winter III WE, Maxwell GL, Tian C, Sundborg MJ, Rose PG, Spriggs D, Muggia F, McGuire WP. Prognostic Factors for Stage IV Epithelial Ovarian Cancer: a Gynecologic Oncology Group Study. Submitted to Cancer.
  12. Allard JE, McBroom JW, Zahn CM, McLeod D, Maxwell GL. Vaginal metastasis and thrombocytopenia from renal cell carcinoma. Gynecol Oncol 2004;Mar;92(3):970-73.
  13. Booth C, Zahn CM, McBroom J, Maxwell GL. Retroperitoneal mullerian carcinosarcoma associated with endometriosis. Gynecol Oncol 2004;93(2):546-9.
  14. Bidus MA, Chandramouli VR, Dainty L, Litzi T, Berchuck A, Barrett JC, Risinger JI, Maxwell GL. Prediction of lymph node metastasis in patients with endometrioid endometrial cancer using expression microarray. Submitted to Gynecologic Oncology for review.
  15. Bidus MA, Maxwell GL, Rodriguez M, Elkas JC, Rose GS: The role of self-collection devices for cytology and human papillomavirus (HPV) DNA testing in cervical cancer screening. Obstetrics and Gynecology (In press)
  16. Bidus MA, Elkas JC, Rodriguez M, Maxwell GL, Rose GS: The clinical utility of the diagnostic endocervical curettage. Obstetrics and Gynecology (In press)
  17. Greer JB, Modugno F, Allen G, Ness R. Androgenic Progestins in Oral Contraceptives and the Risk of Epithelial Ovarian Cancer. Obstet Gynecol 2005;105:000-000.
  18. Baysal BE, DeLoia JA, Willett-Brozick JE, Goodman MT, Brady MF, Modugno F, Lynch HT, Conley YP, Watson P, Gallion HH. Analysis of CHEK2 gene for ovarian susceptibility. Gynecol Oncol 2004;95:62-69.
  19. Modugno F, Ness RB, Allen GO, Schildkraut JM, Davis FG, Goodman MT. Oral contraceptive use, reproductive history, and risk of epithelial ovarian cancer in women with and without endometriosis. Am J Obstet Gynecol 2004;191:733-40.
  20. Sit AS, Modugno F, Hill LM, Martin J, Weissfeld JL. Transvaginal ultrasound measurement of endometrial thickness as a biomarker for estrogen exposure. Cancer Epidemiol Biomarkers Prev 2004 Sep;13(9):1459-65.
  21. Modugno F. Ovarian cancer and polymorphisms in the androgen and progesterone receptor genes: A HuGE review. Am J Epidemiol 2004;159(4):319-335.
  22. Wilcox CB, Baysal BE, Gallion HH, Strange MA, DeLoia JA: High-Resolution Methylation Analysis of the BRCA1 Promoter in Ovarian Tumors: BRCA1 methylation pattern in ovarian tumors. Cancer Genetics and Cytogenetics (In press).
  23. Hsu LC, Kapali M, DeLoia JA, Gallion HH. Centrosome abnormalities in ovarian cancer. Int J Cancer 2005 Feb 20;113(5):746-51.
  24. Peters DG. Kudla DM, DeLoia JA, Chu TJ, Fairfull L, Edwards RP, Ferrell RE. Comparative gene expression analysis of ovarian carcinoma and normal ovarian epithelium by serial analysis of gene expression, Cancer Epidemiology, Biomarkers & Prevention, manuscript accepted.
  25. Thrall M, Gallion HH, Kryscio R, Kapali, M, Armstrong DK, DeLoia JA. BRCA 1 expression in a large series of sporadic ovarian carcinomas:  a Gynecologic Oncology Group study. Submitted to the International Journal of Gynecologic Cancer.
  26. DeLoia JA, Zamboni W, Jones J, Gallion HH. Variable expression of taxane-metobolizing enzymes in ovarian tumors; a potentially novel mechanism of taxane resistance. Submitted to Molecular Cancer Therapeutics.
  27. Spies JB, Cooper JM, Worthington-Kirsch R, Lipman JC, Mills BB, Bennetati JF: Outcome of uterine artery embolization and hysterectomy for leiomyomas: results of a multicenter study. Am J Obstet Gynecol 2004;191:22-31.
  28. Bruno J, Sterbis K, Flick P, McCullough M, Cramp M, Murphy-Skrynarz K, Spies JB: Recovery after uterine artery embolization for leiomyomas: a detailed analysis of its duration and severity. J Vasc Interv Radiol 2004;15:801-7.
  29. Spies JB, Allison S, Flick P, McCullough M, Sterbis K, Cramp M, Bruno J, Jha R: Polyvinyl alcohol participles and tris-acryl gelatin microspheres for uterine artery embolization for leiomyomas: results of a randomized comparative study. J Vasc Interv Radiol 2004;15:793-800.
  30. Spies JB, The Medical Letter, Uterine Artery Embolization for Fibroids, January 2005.
  31. Spies JB, Myers ER, Mulgund, J, Hume, KM, Strain, C. The FIBROID Registry: Report of Structure, Methods, and Initial Results. Prepared for the Agency for Healthcare Research and Quality.
  32. Spies JB, Editoral, Radiographics (in press).
  33. Spies, JB, Myers ER, Worthington-Kirsch R, Mulgund J, Mauro M, Pron, G, Peterson E, Goodwin S. The Fibroid Registry for Outcomes Data (FIBROID) for Uterine Artery Embolization: Outcome from Therapy.
  34. Worthington-Kirsch R, Spies JB, Myers ER, Mulgund J, Mauro M, Pron G, Peterson E, Goodwin S. The Fibroid Registry for Outcomes Data (FIBROID) for Uterine Artery Embolization: Procedure Technique and Short-Term Outcomes
  35. Gierach G, Modugno, F, Ness R, Gestational Length, Timing, and Type of Incomplete Pregnancy in Relation to Ovarian Cancer Risk, Am J of Epidem (in press).
  36. Gierach G, Modugno, F, Ness R, Gender of Offspring and Maternal Ovarian Cancer Risk (submitted to Epidemiology.)
  37. Lyons-Weiler J, Patel SV, Becich MJ, Godfrey T. Tests for finding complex patterns of differential expression in cancers: towards individualized medicine. BMC Bioinformatics 2004, 5:110-116.
  38. Becich MJ, Gilbertson JR, Gupta D, Grzybicki DM and Raab, SS. Pathology and Patient Safety: The Critical Role of Pathology Informatics in Error Reduction and Quality Initiatives. Clin Lab Med. 2004 Dec;24(4):913-43.
  39. Mitchell KJ, Becich MJ, Berman JJ, Chapman WW, Gilbertson J, Gupta D, Harrison J, Legowski E, and Crowley RS Implementation and Evaluation of a Negation Tagger in a Pipeline-based System for Information Extraction from Pathology Reports. Med Info. 2004:663-7.
  40. Li S, Becich MJ, Gilbertson J. Microarray Data Mining Using Gene Ontology. Med Info. 2004:778-82.
  41. Gilbertson JR, Gupta R, Nie Y, Patel AA, Becich MJ. Automated Clinical Annotation of Tissue Bank Specimens. MedInfo, 2004: 607-610.
  42. Chandran U, Monzon FA, Becich MJ, Gilbertson J. A new pathology biomarker laboratory. Medinfo. 2004(CD):1546.
  43. Gorelik, E., Edwards, R.P., Feng, X., Marrangoni, A.M., Grandis, J.R., Drenning, S.D., Velikokhatnaya, L., Kwon, J.-A., Lokshin, A. IL-12 Receptor-Mediated Up-Regulation of FasL in Human Ovarian Carcinoma Cells. Int J Cancer 2004, 112:620-7.
  44. Gorelik, E., Landsittel, DP, Marrangoni, AM, Modugno, F, Velikokhatnaya, L, Winans, MT, Bigbee, WL, Herberman, RB, Lokshin, A. Multiplexed Immunobead-Based Cytokine Profiling for Early Detection of Ovarian Cancer. Cancer Epidem Biomarkers Prevention, (in press).
  45. Gorelik, E, Landsittel, D, Winans, M, Marrangoni, AM, Velikokhatnaya, L, and Lokshin, A. IL-8 and anti-IL-8 antibody in ovarian cancer. Submitted to Int J Immunol.
  46. Elieser G, Landsittel, DP, Marrangoni, AM, Modugno, F, Velikokhatnaya L, Winana MT, Bigbee WL, Herberman, RB, and Lokshin, AE. Multiplexed Immunobead-Based Cytokine Profiling for Early Detection of Ovarian Cancer. Cancer Epidem Biomarkers Prevention, (in press).
  47. Landsittel DP, Marrangoni AM, Modugno F, Velikokhatnaya L, Winana MT, Bigbee WL, Gorelik E, Lokshin AE, Exploring joint relationships between cytokine expression and ovarian cancer. Accepted to Dis Markers.
  48. Greer J, Modugno F, and Ness RB. Short term oral contraceptive use and the risk of epithelial ovarian cancer. To appear in Am J Epidemiol.